Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer

For patients with early stage EGFR-mutant–positive (EGFR-M+) NSCLC, curative surgery followed by adjuvant chemotherapy is considered the standard of care. This study evaluated the feasibility and efficacy of longitudinal monitoring of circulating tumor DNA (ctDNA) as a valuable biomarker for early d...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of thoracic oncology 2023-09, Vol.18 (9), p.1199-1208
Hauptverfasser:	Jung, Hyun-Ae, Ku, Bo Mi, Kim, Yeon Jeong, Park, Sehhoon, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Cho, Jong Ho, Kim, Hong Kwan, Choi, Yong Soo, Choi, Yoon-La, Shin, Sun Hye, Jeong, Byeong-Ho, Um, Sang-Won, Kim, Hojoong, Kim, Kyunga, Ahn, Myung-Ju, Kim, Jingook
Format:	Artikel
Sprache:	eng
Schlagworte:	Circulating tumor DNA Early stage Epidermal growth factor receptor Non–small cell lung cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!